Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Closes $2.5M Private Placement

Premium

Rosetta Genomics this week announced that it has entered into a definitive agreement to sell securities to institutional investors in a private placement for aggregate gross proceeds of about $2.5 million.

Specifically, Rosetta will sell 2.5 million ordinary shares at a price of $1.00 per share, and give the purchasers warrants to buy up to 1.25 million ordinary shares at an exercise price of $1.30 per share and warrants to purchase up to 625,000 ordinary shares at an exercise price of $0.01 per share.

Rosetta said it will use the proceeds of the private placement for working capital purposes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more